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First IMP-1-producing Klebsiella
pneumoniae isolate in Turkey
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Two recent articles in CMI have reported the
emergence and spread of different types of
metallo-b-lactamases (MBLs), namely the IMP
and VIM series, SPM-1 and GIM-1, which have
been documented in various geographical areas
[1,2]. Recently, SIM-1 has also appeared as a new
MBL in Korea [3]. We report here a carbapenem-
resistant isolate of Klebsiella pneumoniae that was
found to be positive for MBL production by Etest
MBL strips (AB Biodisk, Solna, Sweden). The
isolate was investigated further and identiﬁed as
an IMP-1 producer.
In April 2003, a K. pneumoniae strain (KP-6852)
was isolated from blood culture of a Turkish child
with neuroblastoma, aged 1 year, who was admit-
ted to the paediatric haematology unit of the
hospital of the Istanbul Faculty of Medicine.
During hospitalisation, the patient was treated
with multiple courses of antimicrobial agents,
including meropenem, before the isolation of the
imipenem-resistant K. pneumoniae strain, and was
eventually discharged after successful treatment
with ciproﬂoxacin.
According to Etest results, KP-6852 was resist-
ant to imipenem, meropenem, cefotaxime, cefta-
zidime, ceftriaxone, piperacillin–tazobactam,
cefoperazone–sulbactam and amikacin, but sus-
ceptible to gentamicin and ciproﬂoxacin [4]. The
MBL Etest revealed a signiﬁcant decrease in the
MIC of imipenem in the presence of EDTA (from
>256 mg ⁄L to < 1 mg ⁄L), suggesting production
of an MBL. No synergy was observed between
clavulanate and cefotaxime or ceftazidime with
the Etest extended-spectrum b-lactamase strips.
Two b-lactamase bands with pIs of 7.6 and 8.2
were identiﬁed by isoelectric focusing, and the
enzyme with a pI of 8.2 hydrolysed imipenem
according to the results of a bioassay [5,6]. PCR
assays were positive for blaIMP-1 and blaOXA-10-like
[7,8]. None of the blaOXA-48, blaPER, blaTEM, blaSHV
or blaCTX-M genes were ampliﬁed by PCR [9–13].
DNA sequencing, followed by comparative ana-
lysis with published sequences, revealed the
presence of an IMP-1 gene in this isolate. Only
low-level imipenem resistance was transferable
by conjugation, probably because of low-level
expression of the enzyme in the transconjugants,
or the lack of additional resistance mechanisms,
such as a porin deﬁciency. A 50-kb plasmid
was detected in the transconjugants by plasmid
analysis [14].
VIM-type enzymes in both Enterobacteriaceae
and non-Enterobacteriaceae have been reported
recently from Turkey [15,16], but this is the ﬁrst
report of an IMP-type enzyme in Turkey. Ana-
lysis of carbapenem resistance in K. pneumoniae is
important, ﬁrst because IMP-1 is encoded by
extrachromosomal elements and rapid horizontal
transmission of carbapenem resistance is possible
among bacteria, and second, because K. pneumo-
niae is considered to be a nosocomial reservoir
and source of transmission of resistance plas-
mids.
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Breakthrough pneumococcal meningitis in a
patient treated with pristinamycin
10.1111/j.1469-0691.2006.01485.x
We read with interest the paper in CMI by Hsueh
et al. [1] concerning increasing resistance tomacro-
lides in Streptococcus pneumoniae despite a > 50%
decrease inmacrolide consumption.Wewould like
to stress the importance of possible clinical thera-
peutic failures caused by macrolide-resistant
S. pneumoniae in patients treated with distantly
related compounds such as pristinamycin.
Pristinamycin has been used widely in France
for nearly 50 years in the treatment of staphylo-
coccal and streptococcal infections, including
those caused by S. pneumoniae and strains resist-
ant to macrolides or related compounds [2,3].
Since our report of the ﬁrst macrolide-resistant
S. pneumoniae in France [4], > 50% of all French
S. pneumoniae isolates have become resistant to
macrolides, which is the highest reported preval-
ence in the western world, although lower than
that in south-east Asia. About 97% of these
isolates are of the macrolides, lincosamides,
streptogramins (MLSB) phenotype (E. Varron,
personal communication). Despite this high pre-
valence, > 99% of the macrolide-resistant isolates
remain fully susceptible to pristinamycin, with a
mode MIC of 0.25–0.5 mg ⁄L (25th Reunion Inter-
disciplinaire de Chimothe´rapie Anti-Infectieuse,
Paris 2005, abstract 346 ⁄ 63p).
Pristinamycin is amixture of two compounds, A
(Pri II) and B (Pri I), which are produced naturally
by Streptomyces pristinaespiralis. Each compound is
bacteriostatic, but their association is synergic and
bactericidal. Despite resistance to compound B in
MLSB-resistant streptococci, the synergic activity is
not abolished, and this prevents the emergence
of resistance to the combination. Quinupristin ⁄
dalfopristin, a semisynthetic derivative, has very
similar activity [6]. However, diminished killing of
these strains bypristinamycinhas beenobserved in
some studies [7,8], and we have observed the
occurrence of a breakthrough case of meningitis
caused by a macrolide-resistant S. pneumoniae in a
patient treated with pristinamycin.
A woman aged 55 years was hospitalised on 31
October 2005 with a clinical diagnosis of pneu-
monia. Upon examination, she had clear signs of
meningitis,with cephalea, vomiting, neck stiffness,
a vast array of neurological disorders, and a
temperature of 39.5C. During the previous
10 days, she had been treated with pristinamycin
2 · 1 gdaily for an acute bronchitis. She had 10 600
white blood cells ⁄mm3 with 92% neutrophils, and
a C-reactive protein level of 113 mg ⁄L. The cere-
brospinal ﬂuid contained 674 cells ⁄mm3 with 95%
neutrophils, and numerous S. pneumoniae cells
were observed following Gram’s stain. Two blood
cultures were found to be positive in < 24 h. The
isolates from the spinal ﬂuid and blood were
identical, with low-level resistance to b-lactams
(MICs: penicillin G 0.75 mg ⁄L; amoxycillin and
cefotaxime 0.5 mg ⁄L), resistance to tetracyclines,
co-trimoxazole, macrolides and related com-
pounds. The MIC of pristinamycin was 0.25 mg ⁄L,
with a minimum bactericidal concentration (MBC)
of 2 mg ⁄L. The strain belonged to serotype 19 A,
which has emerged during recent years as being
responsible for serious pneumococcal infections,
including cases of meningitis (E. Varon, personal
communication). The patient was treated with
ceftriaxone 6 g ⁄day and vancomycin 6 g ⁄day for
only 5 days because of acute renal failure. She also
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